Dublin (IE), Cambridge (UK) | 23 January 2019: Inflazome’s drug discovery and development efforts highlighted in Nature Biotechnology News Article.Following on from a 2018 Science Translational Medicine publication validating the NLRP3 inflammasome as a potential therapeutic target in Parkinson’s Disease (here), Nature Biotechnology highlights the role and potential of NLRP3 in Parkinson’s Disease and Inflazome’s focused efforts to treat this debilitating disease with our potent, proprietary NLRP3 inhibitors.


Read the full article here